GlassScriptPhysician profile
Connor Ericksen
NPI 1457882391
$1,282.21
in general payments reported to CMS, 2019-2025
14 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $42.73 · 2021: $179 · 2022: $150 · 2023: $174 · 2024: $412 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.51 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $320.89 | 2020-2025 | Rocklatan |
| Genentech USA, INC. | $219.57 | 2023-2024 | Vabysmo |
| Allergan, INC. | $184.18 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $126.00 | 2021-2023 | Acthar |
| Astellas Pharma US INC | $101.20 | 2024 | Izervay |
| Bausch & Lomb Americas INC. | $71.96 | 2023-2024 | Xipere, Vyzulta, Lotemax Sm |
| Regeneron Healthcare Solutions, INC. | $58.03 | 2025 | Eylea Hd |
| Genentech, INC. | $42.51 | 2024 | Susvimo |
| Abbvie INC. | $39.54 | 2025 | |
| Oyster Point Pharma, INC. | $34.27 | 2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $23.83 | 2025 | Xdemvy |
| Glaukos Corporation | $21.86 | 2021 | |
| Apellis Pharmaceuticals, INC. | $20.28 | 2025 | Syfovre |
| Dompe US, INC. | $18.09 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Ericksen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.